Eidos Therapeutics Presents Data from its Phase 1 Clinical Trial of AG10 at the 22nd Annual Scientific Meeting of the Heart Failure Society of America
September 17, 2018 08:00 ET
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) announced the presentation of results from its Phase 1 clinical trial of AG10 during a poster session...
Eidos Therapeutics Announces Publication of AG10 Molecular Design in Journal of Medicinal Chemistry
August 23, 2018 08:00 ET
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced publication of the design and preclinical characterization of its lead product...
Eidos Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 07, 2018 16:30 ET
|
Eidos Therapeutics, Inc.
SAN FRANCISCO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in...